A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

PHASE3CompletedINTERVENTIONAL
Enrollment

467

Participants

Timeline

Start Date

October 10, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Actinic Keratosis
Interventions
DRUG

Imiquimod

Cream, generic formulation of the brand product.

DRUG

Zyclara®

Cream, brand product.

DRUG

Vehicle Cream

Vehicle cream in the same image of the generic imiquimod. Has no active ingredient.

Trial Locations (27)

27103

Site 18, Winston-Salem

27262

Site 4, High Point

28403

Site 11, Wilmington

29644

Site 20, Fountain Inn

33486

Site 28, Boca Raton

33511

Site 26, Brandon

Site 27, Brandon

35025

Site 1, Birmingham

37203

Site 5, Nashville

37917

Site 6, Knoxville

46032

Site 7, Carmel

46168

Site 22, Plainfield

46256

Site 15, Indianapolis

46617

Site 23, South Bend

48038

Site 16, Clinton Township

55432

Site 13, Fridley

60005

Site 3, Arlington Heights

61820

Site 17, Champaign

77056

Site 2, Houston

77845

Site 12, College Station

78759

Site 14, Austin

80220

Site 24, Denver

83704

Site 21, Boise

87106

Site 9, Albuquerque

90045

Site 8, Los Angeles

94538

Site 10, Fremont

97223

Site 25, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT02120898 - A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses | Biotech Hunter | Biotech Hunter